Nextleaf Solutions Ltd. (” Nextleaf Solutions “, ” OILS “, or the ” Company “) ( CSE: OILS ) ( OTCQB: OILFF ), Canada’s most innovative cannabis extractor, is pleased to announce that its wholly-owned subsidiary Nextleaf Labs Ltd. (“ Nextleaf Labs ”), a Health Canada licensed standard processor, has entered into a Cannabis Extraction Agreement (the “ Agreement ”) with Natural MedCo Ltd.(“ NMC ”), a wholly-owned subsidiary of Eve & Co Incorporated (“ E ve & Co ”) ( TSX-V: EVE ) ( OTCQ B : EEVVF ). NMC is based in Strathroy, Ontario and operates over one million square feet of licensed production and distribution through provincial adult-use channels and international markets.

Cannabis Extraction Agreement


Pursuant to the Agreement, NMC will provide cannabis biomass to be processed into distilled THC and CBD oils at Nextleaf’s closed-loop extraction plant in Metro Vancouver. The resulting bulk THC and CBD oils will be sold by Nextleaf Labs through its Commercial Partners Program and the wholesale market, with the net proceeds of such sales to be shared by Nextleaf Labs and NMC. The initial term of the Agreement will end on the earlier of (a) 12 months, and (b) the date upon which 5,000 kilograms of cannabis biomass has been processed, and automatically renews thereafter for successive one-year terms.

Nextleaf Solutions’ investment in IP and its existing fixed asset base provides a robust platform to scale, and a clear competitive advantage to supply low-cost cannabinoid distillate produced at the Company’s ultra-efficient cannabis oil refinery in British Columbia.

“We are excited for the opportunity to support the launch of Eve & Co’s female-focussed cannabis 2.0 product lines in Canada,” stated Nextleaf Solutions’ CFO, Charles Ackerman. “Given our partner’s European Union certificate of Good Manufacturing Practise Compliance, and their ability to distribute into Germany, we expect to have opportunities to supply global markets with bulk THC and CBD oils and differentiated products,” continued Ackerman.

“We are excited about the opportunity to work with Nextleaf, which is such a ground-breaking company, and the opportunities our partnership will bring,” said Melinda Rombouts, CEO and President of Eve & Co. “Alliance with this group adds another revenue stream, which aligns well with our 2.0 female-focussed product line and exports to the European Union.”

About Nextleaf®

OILS is Canada’s most innovative cannabis extractor, developing technology for extracting and distilling cannabinoids. OILS wholesales THC and CBD oils and provides extraction services through its wholly owned subsidiary Nextleaf Labs Ltd., a Health Canada licensed processor. The Company owns a portfolio of over 50 issued patents and over 50 pending patents for the extraction, purification, and delivery of cannabinoids.  The Company’s proprietary closed-loop extraction plant in Metro Vancouver has a design capacity to process 600 kg per day of dried cannabis biomass into distilled oils.

Nextleaf Solutions trades as OILS on the Canadian Securities Exchange, OILFF on the OTCQB Market in the United States, and L0MA on the Frankfurt Stock Exchange.

Follow OILS across social media platforms: Twitter , LinkedIn , Facebook , and Instagram .

www.nextleafsolutions.com

For more information please contact:
Jason McBride
604-283-2301 (ext. 219)
investors@nextleafsolutions.com

On behalf of the Board of Directors of OILS,

Paul Pedersen, CEO

About Eve & Co.

Eve & Co, through its wholly-owned subsidiary NMC, holds cultivation and processing licences under the Cannabis Act (Canada) for the production and sale of various cannabis products, including dried cannabis, cannabis plants and extraction of cannabis oil and has received its European Union certificate of Good Manufacturing Practice. NMC was Canada’s first female-founded licensed producer of medicinal marijuana and received its cultivation licence from Health Canada in 2016. Eve & Co is led by a team of agricultural experts and has a licensed 1,000,000 square foot greenhouse located in Strathroy, Ontario.

For further information, please contact:

Melinda Rombouts
President and Chief Executive Officer
Eve & Co Incorporated
Telephone: (855) 628-6337

Rory Taylor
Interim Chief Financial Officer
Eve & Co Incorporated
Telephone: (855) 628-6337

CAUTIONARY STATEMENT

Certain statements contained in this press release constitute “forward-looking statements”. All statements other than statements of historical fact contained in this press release, including, without limitation, those regarding the Company’s ability to capitalize on its IP portfolio, the Company and NMC’s strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words “believe”, “expect”, “aim”, “intend”, “plan”, “continue”, “will”, “may”, “would”, “anticipate”, “estimate”, “forecast”, “predict”, “project”, “seek”, “should” or similar expressions or the negative thereof, are forward-looking statements. These statements are not historical facts but instead represent only the Company and Eve & Co’s expectations, estimates and projections regarding future events. These statements are not guarantees of future performance and involve assumptions, risks and uncertainties that are difficult to predict. Therefore, actual results may differ materially from what is expressed, implied or forecasted in such forward-looking statements. Additional factors that could cause actual results, performance or achievements to differ materially include, but are not limited to the risk factors discussed in the Company’s MD&A and Eve & Co’s MD&A, respectively, for the most recent fiscal period. The Company and Eve & Co’s management provides forward-looking statements because it believes they provide useful information to investors when considering their investment objectives and cautions investors not to place undue reliance on forward-looking information. Consequently, all of the forward-looking statements made in this press release are qualified by these cautionary statements and other cautionary statements or factors contained herein, and there can be no assurance that the actual results or developments will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, the Company and Eve & Co, as applicable. These forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update or revise them to reflect subsequent information, events or circumstances or otherwise, except as required by law. The CSE has not reviewed or approved this press release.

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Primary Logo

News Provided by GlobeNewswire via QuoteMedia

 Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Keep reading... Show less

Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Aurora securities between February 13, 2020, and September 4, 2020, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/acb .

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

Keep reading... Show less

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Keep reading... Show less

Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Aurora Cannabis Inc. (NYSE: ACB) from February 13, 2020 through September 4, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Aurora Cannabis Inc. investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email info@pawarlawgroup.com for information on the class action.

Keep reading... Show less

The Israeli cannabis market is picking up with a new supply deal from a Canadian producer.

Also this week, new data showed sales of Canadian cannabis edible products may be stalling.

Keep reading... Show less